Uniondale, NYNCT07137494Now EnrollingIRB Ready

Primary Central Nervous System (CNS) Lymphoma Clinical Trial in Uniondale, NY

Access cutting-edge primary central nervous system (cns) lymphoma treatment through this clinical trial at a research site in Uniondale. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Uniondale location

Preparing your pre-screening questions…

Expert Care in Uniondale

Access primary central nervous system (cns) lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related primary central nervous system (cns) lymphoma treatment provided free

Apply for This Uniondale Location

Check if you qualify for this primary central nervous system (cns) lymphoma clinical trial in Uniondale, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Uniondale

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Uniondale site if eligible
  4. 4Begin participation

About This Primary Central Nervous System (CNS) Lymphoma Study in Uniondale

This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Men and women who are at least 18 years of age on the day of consenting to the study.
Histologically documented primary or secondary central nervous system lymphoma of DLBCL subtype
Relapsed/refractory primary or secondary CNSL patients. All relapsed//refractory patients need to have received at least one prior CNS-directed methotrexate-based therapy. There is no restriction on the number of recurrences.
For relapsed patients, parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) within 21 days of study consent.
For refractory patients, there must be residual disease after their last line of therapy.
For patients with leptomeningeal disease only, CSF cytology and/or flow cytometry must document CSF findings consistent with CSF involvement by lymphoma and/or imaging findings consistent with CSF disease within 21 days of study registration (at the discretion of the investigator).
Creatinine Clearance ≥ 40 ml/min/m2, direct bilirubin ≤2.0 mg/100 ml, AST and ALT ≤3.0x upper limit of normal (ULN)
Adequate pulmonary function as assessed by ≥90% oxygen saturation on room air by pulse oximetry.
Must be able to tolerate both MRI and CT scans
Must be able to tolerate lumbar puncture and/or Ommaya taps
Must have been either off corticosteroids, or on a stable or decreasing dose of dexamethasone equivalent ≤ 2 mg daily for 7 days before apheresis and 72 hours prior to CAR T cell infusion o Use of corticosteroids to treat CAR T cell toxicities per MSKCC guidelines is permitted

Exclusion Criteria

ECOG performance status \>2 o Patients with ECOG status of 2 will be enrolled at the discretion of the PI
Active systemic lymphoma (i.e. involvement outside of the CNS)
If the most recent CSF or brain tissue sample demonstrates absence of CD19 expression
Size of any single CNS lymphoma lesion exceeds 3 cm in maximal diameter in eloquent brain structures.
Prior treatment of systemic lymphoma with CD19-targeted CAR T cells
Pregnant or lactating patients. Patients of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished.
Impaired cardiac function (LVEF \<40%) as assessed by most recent ECHO in the last 1 year.
Patients with autoimmune disease requiring systemic T cell-suppressive therapy.
Patients with following cardiac conditions will be excluded:
New York Heart Association (NYHA) stage III or IV congestive heart failure
Myocardial infarction ≤6 months prior to enrollment
History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration ≤6 months prior to enrollment
Patients with ocular lymphoma in the absence of other CNS involvement
Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C, or 3 months since allogeneic hematopoietic stem cell transplantation, prior to starting the study drug, or the patient has not recovered from the side effects of such therapy.
Patients with HIV
Patients with active hepatitis B or hepatitis C infection (as manifested by either detectable hepatitis B virus DNA by PCR, hepatitis virus C RNA by PCR, or positivity for hepatitis B surface or core antigen)
Patients with uncontrolled systemic fungal, bacterial, viral or other infection at time of leukapheresis or at time of CAR T cell infusion
Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of skin
Patients exposed to immune checkpoint inhibitor within 8 weeks
Use of herbal supplements are not allowed on study
Any other issue which, in the opinion of the treating physician or PI, would make the patient ineligible for the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Uniondale?

Yes, this clinical trial (NCT07137494) has an active research site in Uniondale, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Primary Central Nervous System (CNS) Lymphoma Treatment Options in Uniondale, NY

If you're searching for primary central nervous system (cns) lymphoma treatment options in Uniondale, NY, this clinical trial (NCT07137494) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Uniondale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced primary central nervous system (cns) lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all primary central nervous system (cns) lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Uniondale, NY

See all lymphoma clinical trials recruiting in Uniondale — not just this study.

Browse Lymphoma Trials in Uniondale →

Browse More Trials by Condition

Lymphoma TrialsRheumatoid Arthritis TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Uniondale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Uniondale, NY